Palatin Technologies Inc. (PTN)

[eicoman]

femprox is a strong competitor to BMT, imo

Femprox is the same drug as Vitaros, although in different concentration. Femprox works by the same mechanism in women as in men, topical increased blood flow to the target area with no systemic effects.
Study: http://www.ncbi.nlm.nih.gov/pubmed/9138056 Conclusion: Vaginal engorgement and clitoral erection depend on increased blood inflow.

Women get erections too. That’s why Vitaros ED drug approval points to Femprox approval as well. The clitoris has erectile tissue just like the penis.
Femprox is also placed on the G-Spot providing vaginal engorgement. Furthermore, the clitoris is long internally, and most likely accounts for vaginal orgasm due to stimulation of the clitoris internally at the G-Spot area. The G-Spot exists – more like a small area – Femprox increases blood flow to the G-Spot as well.
http://www.empowher.com/sexual-well-being/content/what-should-women-know-about-g-spot-dr-goldstein-video see Dr Goldstein comments KOL – Key Opinion Leader

NexAct transdermal permeation enhancer clearly makes the difference, as shown by Vivus.
Vivus ran clinical trials using a topical alprostadil product for FSAD , and the trials were unsuccessful because they could not get much beyond the placebo effect. But APRI has seven studies including: a PH2 trial in the USA with 100 women which showed a positive trend towards higher doses, and a PH3 trial in China with 400 women, the PH3 trial had better trial design, which showed for the highest 900-µg dose that significant and clinically relevant improvements in primary arousal success and secondary efficacy outcomes (FSFI) and Global Assessment Questionnaire (GAQ) and FSDS were achieved.

The best aspect of Femprox is its safety profile, only side effects are mild to moderate transient irritation at the application site, lessens over time with usage, low study dropout rates. No rare or serious systemic effects like most drugs.

2 of the main physiological causes of FSIAD are vascular and neurological.
PGE1 (alprostadil) is a powerful vasodilator and directly increases uptake and release of neurotransmitters, addressing both of these causes.
http://www.ncbi.nlm.nih.gov/pubmed/19017254
J Sex Med. 2009 Jan;6(1):81-90. doi: 10.1111/j.1743-6109.2008.01060.x. Epub 2008 Nov 5.
The effects of alprostadil on hypothalamic and amygdalar function and the central expression of oxytocin: a potential central role of alprostadil cream.
Sun X, Xu L, Zhang J, Guo F, Tang M.